• Apricus Biosciences Inc., of San Diego, said Health Canada granted its request for a pre-new drug submission meeting to obtain regulatory guidance from the agency for MycoVa, its topical treatment for onychomycosis. The meeting is set for July 18, and Apricus expects to obtain feedback regarding the suitability of its Phase III program.